See the DrugPatentWatch profile for Segluromet
Segluromet received European Medicines Agency (EMA) approval on November 20, 2015 [1]. This approval granted marketing authorization for the drug in all 28 European Union member states [1].
What is Segluromet?
Segluromet is a combination medication containing two active ingredients: sitagliptin and metformin [1]. It is prescribed for adults with type 2 diabetes mellitus to improve glycemic control [1]. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin is a biguanide [1].
How does Segluromet work?
The two components of Segluromet work through complementary mechanisms to lower blood glucose levels. Sitagliptin enhances the body's own ability to regulate blood sugar by increasing levels of incretin hormones, which are released after meals [1]. Metformin, on the other hand, works by reducing glucose production in the liver and decreasing glucose absorption in the intestines [1].
When did Segluromet first become available?
Following its EMA approval on November 20, 2015, Segluromet became available to patients in European markets [1]. The specific date of market launch can vary by country.
What are the approved uses for Segluromet?
Segluromet is indicated for adults with type 2 diabetes mellitus who have inadequate glycemic control with diet and exercise and who are already being treated with or are suitable for treatment with both sitagliptin and metformin [1]. It can be used as monotherapy or in combination with other antidiabetic agents when diet and exercise alone are insufficient [1].
What is the difference between Segluromet and Janumet?
Both Segluromet and Janumet are combination medications containing sitagliptin and metformin [2, 3]. They share the same active ingredients and are used for the same indication of type 2 diabetes management. The primary difference lies in their brand names and the pharmaceutical companies that market them. Segluromet is marketed by Merck Sharp & Dohme (MSD) in Europe, while Janumet is also a brand name for sitagliptin and metformin developed by Merck & Co. (MSD's parent company) [2, 3].
Are there any patents for Segluromet?
Information regarding specific patent expiry dates for Segluromet (sitagliptin/metformin) can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides data on patent status and expiry for numerous drugs, including those containing sitagliptin and metformin [4].
What is the regulatory status of Segluromet in other regions?
While the EMA approved Segluromet in 2015, regulatory approval in other regions, such as the United States, would follow separate review processes by agencies like the Food and Drug Administration (FDA). The FDA-approved brand name for the combination of sitagliptin and metformin is Janumet [3].
What are the common side effects of Segluromet?
Common side effects reported with Segluromet (sitagliptin/metformin) include upper respiratory tract infection, nasopharyngitis, and headache [1]. Metformin, a component of Segluromet, can also cause gastrointestinal side effects such as diarrhea, nausea, vomiting, and abdominal discomfort [1].
What are the risks associated with Segluromet?
Serious risks associated with Segluromet include lactic acidosis (a rare but serious complication of metformin), severe and persistent abdominal pain (potentially indicative of pancreatitis), hypoglycemia (especially when used with other antidiabetic agents), hypersensitivity reactions, and vitamin B12 deficiency [1].
What is the clinical data supporting Segluromet's use?
The EMA approval for Segluromet was based on clinical studies demonstrating its efficacy and safety in improving glycemic control in adults with type 2 diabetes. These studies typically evaluated endpoints such as HbA1c reduction and compared the combination therapy to individual components or placebo [1].
Can other companies produce generic versions of Segluromet?
The ability for other companies to produce generic versions of Segluromet depends on patent protection and market exclusivity periods. Once patents expire and any granted exclusivity periods end, generic manufacturers can seek approval to market their own versions of the drug, provided they meet regulatory standards [4].
Sources:
1. European Medicines Agency. (n.d.). Segluromet. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet
2. Merck Sharp & Dohme. (n.d.). Segluromet Product Information. (Specific document not directly linked, but reference to MSD marketing).
3. U.S. Food and Drug Administration. (n.d.). Drug Label Information. (Reference to Janumet as sitagliptin/metformin).
4. DrugPatentWatch.com. (n.d.). Drug Patent Database. Retrieved from https://drugpatentwatch.com/